VIA
DNLI icon

Virtus Investment Advisers’s Denali Therapeutics DNLI Stock Holding History

Virtus Investment Advisers’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.38M Buy
53,688
+38,522
+254% +$792K 0.32% 138
2026
Q1 		$291K Buy
15,166
+371
+3% +$7.38K 0.08% 283
2025
Q4 		$244K Buy
14,795
+7,171
+94% +$121K 0.07% 340
2025
Q3 		$111K Buy
7,624
+1,324
+21% +$19K 0.03% 412
2025
Q2 		$88.1K Sell
6,300
-691
-10% -$9.73K 0.03% 391
2025
Q1 		$95K Buy
+6,991
New +$134K 0.03% 428

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtus Investment Advisers's DNLI Position: Q2 2026 in Review

Virtus Investment Advisers increased its Denali Therapeutics (DNLI) stake by 254% in Q2 2026, buying an estimated $792K and bringing the position to 53,688 shares worth $1.38M. The position accounts for 0.32% of the portfolio, ranked #138.

Virtus Investment Advisers first reported a position in DNLI in Q1 2025 and has held it in 6 quarters since. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Virtus Investment Advisers held 53,688 shares of Denali Therapeutics worth $1.38M as of Q2 2026.
  • Virtus Investment Advisers bought 38,522 Denali Therapeutics shares in Q2 2026, an estimated $792K.
  • Denali Therapeutics made up 0.32% of Virtus Investment Advisers's portfolio in Q2 2026, its #138 holding.
  • Virtus Investment Advisers first reported a position in Denali Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.